Page last updated: 2024-09-05

n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and Cancer of Pancreas

n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide has been researched along with Cancer of Pancreas in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beijnen, JH; Funahashi, Y; Huitema, AD; Keizer, RJ; Schellens, JH; Semba, T; Wanders, J1

Trials

1 trial(s) available for n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and Cancer of Pancreas

ArticleYear
Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.
    The AAPS journal, 2011, Volume: 13, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Dose-Response Relationship, Drug; Female; Humans; Indoles; Integrin alpha2; Male; Mice; Mice, Nude; Middle Aged; Models, Biological; Neoplasm Transplantation; Neoplasms; Nonlinear Dynamics; Pancreatic Neoplasms; Sulfonamides; Treatment Outcome

2011